HCPCS code J3246 – Injection, tirofiban hcl

Key takeaways

HCPCS Code J3246 reports injection of tirofiban HCl (Aggrastat) at 0.25 mg per billing unit.

Divide the total milligrams administered by 0.25 to get the unit count, so 5 mg bills as 20 units.

Medicare Part B covers J3246 when the drug is medically necessary, and pays separately payable doses at 106% of ASP.

In an ambulatory surgical center the drug is bundled into the facility payment, so it is not separately payable there.

Report JZ when nothing is discarded, or JW for the discarded amount, on every single-dose container claim.

J3246 code attributes at a glance

These are the code’s defining attributes as published in the HCPCS Level II file.

According to the Centers for Medicare and Medicaid Services (CMS), HCPCS Level II J-codes are maintained every year. Billers should check code status each January using the CMS HCPCS release files before filing claims for the new year.

Tirofiban HCl: Clinical context and why a J-code applies

Tirofiban (Aggrastat) is a glycoprotein IIb/IIIa receptor antagonist. It blocks platelet aggregation by preventing fibrinogen from binding to the GP IIb/IIIa receptor on activated platelets. Clinically, it is used in acute coronary syndrome (ACS), including unstable angina and non-ST-elevation myocardial infarction (NSTEMI). It usually runs as a continuous intravenous infusion in the hospital or the cardiac catheterization lab.

J-codes exist just for drugs given by non-oral routes: injection, infusion, or inhalation. Tirofiban is given intravenously and is not self-administered, so it falls outside CPT procedure code reporting. An HCPCS Level II J-code is what captures the drug cost on the claim. Billing teams cannot use a CPT code to represent the drug itself. J3246 is the only HCPCS code assigned to tirofiban HCl at the 0.25 mg billing unit.

Do not provide clinical dosing guidance to patients based on billing reference materials. The FDA-approved prescribing information for Aggrastat governs dosing. This article covers billing and coding context only.

How to calculate billing units for J3246

Unit calculation is the single most frequent source of claim errors on J3246. Each billing unit equals 0.25 mg of tirofiban HCl. To determine the correct number of units, divide the total milligrams given by 0.25.

Formula: Units billed = Total mg administered ÷ 0.25 mg per unit

Tirofiban infusions in ACS protocols often run at weight-based rates over 30 minutes for loading, followed by a maintenance infusion. The billing team needs the total milligrams from the administration record, not the infusion rate. Pull the recorded total from the medication administration record (MAR) before calculating units.

When a single-dose container is not fully used, the remainder is drug waste. Modifier JW or JZ must be appended to reflect waste status (see the Modifiers section below). Under-billing units because the container was not empty is a documentation error that reduces reimbursement.

HCPCS Code J3246 Medicare coverage and reimbursement

Medicare Part B covers J3246 when tirofiban is medically necessary and supported by a documented diagnosis. Payment for separately payable Part B drugs comes from the quarterly CMS ASP Drug Pricing File, not the Physician Fee Schedule. That file sets the payment limit at 106% of the drug’s average sales price.

CMS republishes the file every quarter, so check the current limit rather than last quarter’s figure. Payment mechanics also differ by setting. A hospital outpatient department bills under the Outpatient Prospective Payment System. That system packages a drug into the procedure payment when its per-day cost falls below the packaging threshold. A physician office is paid from the same ASP file by its Medicare Administrative Contractor.

Drugs bought through the 340B program are paid at that same ASP plus 6% rate. The ASP minus 22.5% reduction that once applied to 340B-acquired drugs under OPPS ended in 2023. A fee schedule still carrying that cut understates what the claim should pay.

ASC payment status

J3246 is not separately payable in the ambulatory surgical center (ASC) setting, based on the CMS ASC payment indicator. This means the drug cost is bundled into the ASC facility payment rather than paid as a separate line item. Check the current 2026 ASC indicator against the CMS ASC fee schedule before billing in this setting. Indicators are updated every year under the OPPS/ASC final rule.

Medical necessity documentation

Medicare requires medical necessity to be shown on every J3246 claim. The claim must include ICD-10-CM diagnosis codes that align with the FDA-approved indications for tirofiban. Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors (MACs) may specify covered diagnoses for your region. Check the applicable MAC LCD before filing, as coverage criteria vary by contractor.

J3246 NDC crosswalk

The NDC-to-HCPCS crosswalk maps the National Drug Code (NDC) printed on the tirofiban label to J3246 for claim submission. Many payers require the 11-digit NDC on the claim alongside the HCPCS code, so it has to be captured when the drug is given. Practice management software like Pabau records the NDC with the drug charge, which supports cleaner claims management and removes the manual lookup later.

Each manufacturer uses its own NDC number. The same drug from different manufacturers carries different NDC numbers, and all of them map to J3246. Generic tirofiban has been available in the US since 2023, so a pharmacy may hold brand and generic stock at the same time. Always report the NDC from the container actually used, not a reference NDC.

The NLM Clinical Tables HCPCS API and the FDA NDC directory both work for checking current NDC numbers against HCPCS codes. NDC data changes with formulation updates, so check the crosswalk at least once a year and whenever a supplier changes.

Applicable modifiers for J3246

Modifiers tell the payer something about how the drug was used that the base code alone does not capture. For J3246, three modifiers are most commonly relevant. Applying the wrong modifier, or leaving out a required one, can trigger a denial or a compliance audit.

CMS built the JW/JZ pair to create an auditable record of drug waste at the single-dose container level. JZ has been required since July 1, 2023 on claims for separately payable Part B drugs from single-dose containers where nothing was discarded. JW reports the discarded amount on its own line when part of the container is not used.

Tirofiban is supplied in single-dose premixed bags, so one of the two modifiers belongs on every claim where the drug is paid separately. Neither modifier applies when the drug is packaged into a facility payment, because there is no separately payable line to attach it to. Multi-dose container policies differ by payer, so check the MAC’s guidance before applying either modifier outside the single-dose case.

ICD-10 diagnosis codes that support J3246 medical necessity

Every J3246 claim needs at least one ICD-10-CM diagnosis code establishing medical necessity. Tirofiban’s FDA-approved indication is acute coronary syndrome, so the codes below are the ones that usually support the claim. Coverage still depends on the applicable MAC’s Local Coverage Determination. Check the recorded diagnosis against the ICD-10-CM code library before the claim goes out.

Always confirm covered diagnoses against your MAC’s LCD and any applicable National Coverage Determination (NCD) before sending the claim. The code should match the physician’s recorded diagnosis, not a general cardiovascular category code. Two denial codes recur on drug claims. CO-4 says the procedure is inconsistent with the modifier used, and CO-167 says the diagnosis is not covered.

Common billing errors with HCPCS Code J3246

Most J3246 denials come from four common mistakes, and each one lives in a different field of the claim line. The diagram below shows what each field should carry and how it fails.

Incorrect unit count

Billing one unit when 20 should have been billed is the most costly error on J3246 claims. It happens when billers record units as the number of containers used rather than the number of 0.25 mg increments given. The MAR is the only reliable source for total mg; container count does not equal billing units.

Missing NDC on the claim

Many commercial payers and some Medicare fee-for-service contractors require the NDC reported alongside J3246. A claim submitted without one may be returned as unprocessable rather than denied, which delays payment without producing a denial code that explains why. A clean claim carries the code, the units, the NDC and the modifier on the same line.

Wrong or missing modifier

Contractors have been editing claims for correct JW and JZ use since October 2023. A separately payable J3246 line without one of them can be rejected outright. Using JW when nothing was discarded, or JZ when drug was discarded, creates a compliance risk if the claim is audited. The modifier has to match the administration record.

Unbundling in the hospital outpatient setting

In the hospital outpatient department, some drugs are packaged with the facility fee under OPPS rules rather than paid on their own line. Billing J3246 separately when it is packaged into the APC payment for a same-day procedure produces an improper payment. Review the applicable APC assignment before listing the drug as a separate line item in facility billing.

How Pabau keeps J3246 claims accurate from administration to submission

Most drug injection errors happen before billing ever sees the claim. The total milligrams sit in the medication administration record, and the NDC sits on the container. The waste note stays with the nurse who ran the infusion. Billing then rebuilds all three from a chart hunt or a phone call.

Pabau, our practice management software, keeps those details on the charge itself. Staff record the drug, the units given, the NDC and the waste status at the point of care. The charge then carries all four into the claim. No one retypes a number between the record and the payer.

For a billing team, that means fewer lines returned for a missing NDC or a mismatched modifier. The month-end rework list gets shorter too. It also leaves an audit trail that matches the administration record, which is what a post-payment review asks for.

Simplify drug injection billing with Pabau

Track HCPCS J-code units, capture NDC numbers, and submit clean claims for drug injections. Pabau’s claims management workflow keeps billing accurate from documentation through reimbursement.

Book a demo

Conclusion

Three fields decide a J3246 claim. Take the unit count from the medication administration record, the NDC from the container that was used, and the modifier from the waste note. Each one is easy to check at the moment the drug is given, and guesswork an hour later.

So build the check into the administration step rather than the billing queue. A biller working two days later cannot see how much drug reached the patient, and a rebuilt number is what an audit finds first. Book a demo to see how Pabau captures drug units, NDCs and waste modifiers at the point of care.

Continue your research

Need to understand how drug injection billing fits into your broader revenue cycle? What is revenue cycle management covers the full claim lifecycle from charge capture through payment posting.

Struggling with claim rejections on drug codes? Denial codes in medical billing explains the most common payer reason codes and how to respond to each.

Want to reduce manual steps in your drug injection billing workflow? Best medical billing software compares platforms built for US clinical billing, including HCPCS J-code support.

Frequently asked questions